Contribution à l’optimalisation du traitement des tendinopathies chroniques : injection de concentrés plaquettaires chez des patients présentant une tendinopathie rotulienne supérieure Optimization of the treatment of the chronic tendinopathies: injection of platelet-rich plasma among patients with a jumper's knee

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2010-021957-38-BE

Enrollment

Registered

2010-07-20

Start date

2010-10-29

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Jumper's knee or patellar tendinopathy

Interventions

Product Name: Platelet-rich plasma (PRP) Pharmaceutical Form: Injection*

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: unilateral jumper's knee rebel to classic traetment Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: traumatic lesion in the knee (bilaterally) ACL rupture muscle tears

Design outcomes

Primary

Measure	Time frame
Main Objective: To observe effects of platelet-rich plasma (PRP) on the healing process of jumper's knee.;Secondary Objective: To observe decrease of pain after injectyion of PRP;Primary end point(s): Standardization of the treatment of tendinoapthy with PRP injection.	—

Countries

Belgium

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026